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1  | INTRODUC TION
Current	 guidelines	 provide	 insufficient	 support	 for	 cardiovascular	
disease	(CVD)	management	in	older	persons.1	Whereas	a	large	num‐
ber	of	CVD	prediction	models	are	available	for	middle‐aged	adults	
(45‐65	 years),	 for	 older	 persons	 (≥70	 years)	 few	 CVD	 prediction	
models	exist.2‐4	Hence,	in	daily	practice,	general	practitioners	(GPs)	













span.13	 Hence,	 GPs	 pragmatically	 and	 intuitively	 weigh	 additional	
factors	 including	 frailty,	multimorbidity,	quality	of	 life,	 and	 life	ex‐
pectancy	in	their	decision	whether	or	not	to	start	preventive	treat‐
ment.14	 Furthermore,	while	 risk	 of	 death	 from	 non‐cardiovascular	
















and	 free	 from	dementia	 and	 conditions	 likely	 to	 hinder	 success‐
ful	long‐term	follow‐up	according	to	their	GP	(eg,	terminal	illness,	
alcoholism)	were	eligible.	There	was	no	sex	bias	 in	 the	 selection	
of	 participants.	Of	6762	eligible	 older	 adults	 from	116	GP	prac‐
tices	within	26	health	care	centers	(HCC)	in	the	Netherlands,	3526	
(52.1%)	 signed	written	 informed	 consent.	 Recruitment	was	 from	
June	 2006	 through	March	 2009.	 The	 primary	 outcome	was	 de‐




of	 CVD	 at	 baseline	were	 included.	 Since	 no	 effect	 of	 the	 inter‐
vention	was	found	on	CVD,	neither	in	the	total	study	population	
nor	 in	 the	participants	without	a	history	of	CVD,	 the	population	
was	considered	a	cohort.17,18	The	preDIVA	study	was	approved	by	




socio‐demographic	 characteristics,	 cardiovascular	 risk	 factors	
(blood	 pressure,	 type	 2	 diabetes	 mellitus	 [T2DM],	 cholesterol,	
BMI,	 and	 smoking	 habits),	 CRP,	 apolipoproteins,	 current	 medica‐
tion,	 symptoms	 of	 apathy,	 family	 history	 of	 CVD,	 and	 the	 APOE	
genotype.
The	 traditional	 risk	 factors	were	 those	used	 in	 the	SCORE‐OP	
(SCORE	for	older	people)	model:	age,	sex,	systolic	blood	pressure,	
smoking	 status,	 total	 cholesterol	 (TC),	 high‐density	 lipoprotein	
cholesterol	 (HDL),	 and	 T2DM.4	 Eleven	 potential	 additional	 CVD	
predictors	were	selected	based	on	the	literature	and	availability	 in	
our	dataset:	family	history	of	CVD,	polypharmacy,	antihypertensive	
medication	 (AHM)	 use,	 physical	 activity,	 BMI,	 apathy	 symptoms,	






physical	 activity	 questionnaire	 (LAPAQ)	 and	 defined	 as	 physically	
active	according	 to	 the	World	Health	Organization.17,20	Symptoms	








and	 peripheral	 arterial	 disease).	 In	 concordance	with	well‐known	
cardiovascular	 prediction	 models	 in	 adults,	 a	 pragmatic	 outcome	
measure	was	chosen,	which	meets	GP	and	older	patients’	prefer‐




the	 EMR	 and	 hospital	 discharge	 letters.	 Subsequently,	 this	 infor‐
mation	 was	 evaluated	 by	 an	 independent	 outcome	 adjudication	
committee.17

































Subsequently,	we	 tested	 for	 interaction	 among	 traditional	 risk	
factors,	because	 the	association	between	potential	 risk	 factors	on	
the	outcome	might	depend	on	other	risk	factors.4,6	Models	were	not	







competing	 risks	 of	 non‐cardiovascular	 death,	 using	 the	 R	 library	
“riskRegression.”25,26	The	event	was	defined	as	first	CVD	event,	the	
competing	event	as	non‐cardiovascular	mortality.
2.5 | Model performance and discriminative ability
Discriminative	ability	was	calculated	and	compared	between	models	
using	the	inverse	probability	of	censoring	weighted	(IPCW)	C‐index.	
Models	 were	 internally	 validated	 using	 bootstrapping.	 Calibration	







explore	 the	 impact	 of	 cardiovascular	medication,	 analyses	were	 re‐
peated	in	subgroups	of	participants	(a)	without	baseline	cardiovascu‐
lar	medication	use,	(b)	without	cardiovascular	medication	at	baseline	
nor	 during	 the	 first	 4	 years	 of	 follow‐up,	 and	 (c)	 in	 the	 control	 and	
intervention	condition	of	preDIVA.	Next,	we	explored	the	impact	on	
predictive	value	and	predictor	selection	of	using	cardiovascular	medi‐
cation	 (antihypertensive	 and	 cholesterol‐lowering	 drugs)	 in	 patients	
with	the	highest	cardiovascular	risk.	For	this,	backward	selection	was	
performed	on	a	model	 including	all	18	variables,	 in	which,	 for	poly‐




















For	 all	 traditional	 and	 additional	 predictors,	 linear	 relations	
between	 predictors	 and	 the	 outcome	 variable	 were	 appropriate.	





Table	2	shows	 the	 results	of	 the	Cox‐regression	analyses	after	
shrinkage,	when	 including	all	 traditional	 risk	 factors	 (model	1)	and	
when	 including	 variables	 that	 remained	 relevant	 after	 backward	
selection	(model	2).	Within	model	1,	the	strongest	predictors	were	
active	smoking	 (HR	1.85	 [95%	CI	1.41‐2.43]),	T2DM	(1.63	 [95%	CI	
1.24‐2.13]),	and	male	sex	(1.32	[95%	CI	1.05‐1.65]).	Of	the	additional	
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bined	 cardiovascular	 morbidity	 and	 mortality	 for	 older	 persons,	
Table	 S2	 shows	beta‐coefficients	 for	 each	 risk	 factor	 of	models	1	
TA B L E  1  Baseline	characteristics	of	participantsa 
Baseline characteristics Overall (n = 1811)
Without incident CVD 
(n = 1534)
With incident CVD 
(n = 277) P‐value
Demographics
Age	in	y,	mean	(SD) 74.1	(2.4) 74.1	(2.4) 74.2(2.5) 0.36
Sex,	male	(%) 717	(39.6) 588	(38.3) 129	(46.6) 0.01
Educational	level,	no.	(%)
<7	y 392	(21.8) 330	(21.5) 62	(22.4) 0.39
7‐12	y 1169	(65.1) 1000	(65.2) 169	(61.0)
>12	y 235	(13.1) 193	(12.6) 42	(15.2)
Caucasian,	no.	(%) 1741	(97.8) 1474	(96.1) 267	(96.4) 0.11
Traditional	cardiovascular	risk	factors
SBP	in	mm	Hg,	mean	(SD) 155.6	(20.6) 154.9	(20.2) 158.9	(22.2) 0.01
Total	cholesterol	in	mmol/L,	mean	(SD) 5.51	(1.04) 5.52	(1.03) 5.42	(1.12) 0.16
HDL‐cholesterol	in	mmol/L,	mean	(SD) 1.56	(0.42) 1.57	(0.42) 1.50	(0.40) 0.01
Type	2	diabetes,	no.	(%) 302	(16.7) 236	(15.4) 66	(23.8) <0.001
Current	smoking,	no.	(%) 214	(11.8) 161	(10.5) 53	(19.1) <0.001
Additional	cardiovascular	risk	factors
LDL	cholesterol	in	mmol/L,	mean	(SD) 3.35	(2.74‐3.95) 3.36	(2.75‐3.95) 3.23	(2.63‐3.93) 0.23
C‐reactive	protein	(CRP),	mg/L,	median	(IQR) 2.00	(1.00‐4.00) 2.00	(1.00‐3.50) 2.00	(1.00‐4.00) 0.03
Circulating	apolipoproteins	A1	(g/L),	mean	(SD) 1.51	(0.29) 1.52	(0.29) 1.46	(0.28) <0.001
Circulating	apolipoproteins	B	(g/L),	mean	(SD) 1.00	(0.25) 1.00	(0.25) 1.00	(0.26) 0.96
Apolipoprotein	E	gene	variants,	no.	(%)
Ɛ2	‐	Ɛ2 7	(0.4) 5	(0.3) 2	(0.7) 0.89
Ɛ2	‐	Ɛ3 237	(13.1) 202	(13.2) 35	(12.6)
Ɛ3	‐	Ɛ3 890	(49.1) 759	(49.5) 131	(47.3)
Ɛ3	‐	Ɛ4 365	(20.2) 311	(20.3) 54	(19.5)
Ɛ4	‐	Ɛ4 35	(1.9) 31	(2.0) 4	(1.4)
BMI	(kg/m2),	mean	(SD) 27.3	(4.3) 27.34	(4.3) 27.36	(4.2) 0.93
Polypharmacy	(≥5	medicine),	no.	(%) 378	(20.9) 299	(19.5) 79	(28.5) <0.001
Use	of	antihypertensive(s),	no	(%) 760	(42.0) 625	(40.7) 135	(48.7) 0.01
Family	history	of	CVDb,	no.	(%) 262	(14.5) 217	(14.1) 45	(16.2) 0.40
Physically	active	(WHO),	no.	(%) 1587	(89.7) 1347	(87.8) 240	(86.6) 0.33
Symptoms	of	apathy	(GDS3A),	no.	(%)
0 1042	(57.7) 906	(59.1) 136	(49.1) 0.01
1 484	(26.8) 402	(26.2) 82	(29.6)
2 199	(11.0) 160	(10.4) 39	(14.1)













age	70	 and	75,	 a	 chart	 based	on	 traditional	 risk	 factors	 (model	 1,	
Equation	S1)	was	developed,	presenting	five‐year	absolute	risks	of	
CVD	morbidity	or	mortality	(Figure	S1).27

























follow‐up	 (n	=	726),	 and	 subgroups	 for	 the	 control	 and	 intervention	
condition	of	preDIVA	did	not	alter	the	results	for	model	1	(Table	S3).




relevant	 predictors	 (Table	 S4,	Model	 5).	 In	 a	 sensitivity	 analysis	
adding	 cholesterol‐lowering	 drugs	 as	 a	 variable	 to	 the	 complete	
model	 with	 18	 variables,	 the	 HR	 for	 cholesterol‐lowering	 drugs	
was	1.02	(95%	CI	0.72‐1.43)	and	HRs	of	the	other	18	variables	in	
the	model	did	not	change.
TA B L E  2  Hazard	ratios	for	traditional	and	additional	risk	factors	for	CVD	morbidity	and	mortality
Predictor category Predictors
Cox‐PH models Fine‐Gray models
Model 1: traditional 
risk factors






Model 4: variables 
of model 2
HR (95% CI) HR (95% CI) HR (95% CI)b HR (95% CI)b
Traditional	risk	factors Age 1.03	(0.99‐1.08) 1.03	(0.98‐1.08) 1.03	(0.99‐1.08) 1.03	(0.98‐1.08)
Male 1.32	(1.05‐1.65) 1.45	(1.16‐1.81) 1.31	(1.04‐1.64) 1.42	(1.14‐1.78)
Smoking	status 1.85	(1.41‐2.43) 1.83	(1.38‐2.43) 1.76	(1.34‐2.30) 1.73	(1.31‐2.28)
SBP	per	mm	Hg 1.01	(1.00‐1.01)  1.01	(1.00‐1.01)  
Total	cholesterol	per	
mmol/L
1.05	(0.94‐1.18)  1.05	(0.93‐1.18)  
HDL	per	mmol/L 0.81	(0.61‐1.09)  0.83	(0.63‐1.10)  
T2DM 1.63	(1.24‐2.13) 1.44	(1.09‐1.89) 1.60	(1.23‐2.08) 1.40	(1.07‐1.83)
Additional	risk	factors Polypharmacy  1.41	(1.08‐1.83)  1.40	(1.08‐1.82)
Symptoms	of	apathy  1.19	(1.05‐1.34)  1.18	(1.05‐1.33)




























In	 two	 studies,	 SBP,	HDL‐cholesterol,	 and	 total	 cholesterol	 re‐
mained	among	the	best	predictors	for	combined	CVD	morbidity	and	
mortality,31,32	and	in	one	study,	SBP	had	no	predictive	value	and	TC	
and	HDL	only	when	 no	 new	 variables	 (CRP,	 homocysteine,	waist‐
to‐hip	 ratio,	 and	 self‐reported	 health)	 were	 added	 to	 the	model.3 
In	 another	 study,	T2DM,	 smoking,	 and	HDL,	but	not	SBP	and	TC,	
were	predictors	for	coronary	heart	disease.31	In	our	study,	SBP,	total	
cholesterol,	 and	HDL‐cholesterol	 had	no	 relevant	 predictive	 value	
beyond	the	six	selected	predictors,	which	is	in	line	with	the	theory	
of	 reverse	 epidemiology	 in	 older	 persons.6,28	 Differences	 among	
studies	 can	 be	 explained	 by	 the	 differences	 in	 study	 populations	









our	 study,	 these	 two	 variables	were	 predictors	 for	 fatal	 and	 non‐
fatal	CVD	in	older	persons.	Polypharmacy	as	a	predictor	 is	consis‐
tent	with	a	previous	study	with	1196	older	people	(aged	≥	65	years)	
where	 “number	 of	 medications”	 was	 identified	 as	 an	 additional	
predictor	 for	 fatal	 CVD.29	 Polypharmacy	 is	 a	 complex	 product	 of	
patient	 characteristics,	physician	management,	 and	patient	prefer‐
ences.14	However,	it	is	easy	to	ascertain	and	can	therefore	easily	be	




of	 polypharmacy,	 although	 the	 use	 of	 antihypertensive	 or	 choles‐
terol‐lowering	medication	were	no	predictors	on	their	own.	Besides,	
this	does	not	disqualify	polypharmacy	as	a	predictor,	since	in	daily	




















We	 provided	 models	 with	 and	 without	 accounting	 for	 com‐
peting	 risk.	Norway	 is	 the	 first	country	 to	 include	CVD	prediction	


















our	 study).3,32	 Additionally,	 there	were	 few	 exclusion	 criteria,	 and	
excluded	 participants	 are	 generally	 not	 considered	 for	 CVD	 risk	
calculation.	The	24%	of	participants	with	missing	predictors	at	the	
baseline	were	retained	in	the	analyses	by	using	multiple	imputation.	
Besides,	 results	of	 complete	case	analyses	did	not	differ	 from	 the	
main	analyses.	The	models,	 therefore,	appear	valid	for	use	 in	non‐
acute	primary	care	consultations.
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a	 5‐year	 prediction	 horizon,	 we	 concede	 to	 GP	 and	 older	 patient	
preferences.13
Treatment	 of	 baseline	 risk	 factors	 could	 have	 reduced	 overall	
predictive	 ability	 in	our	population	of	older	people.34	However,	 in	
analyses	 including	cholesterol‐lowering	and	antihypertensive	med‐







may	 result	 in	 false‐positive	 or	 false‐negative	 results,	 but	 our	 re‐
sults	 are	 robust	 using	 different	methods,	 and	 in	 sensitivity	 analy‐
ses.	 Finally,	 evaluation	of	 additional	 factors	was	 limited	 to	 factors	
available	 in	our	dataset.	There	might	be	other	 factors	with	 strong	
predictive	ability	not	available	in	our	data.28,35
Our	 results	provide	 insight	 into	absolute	 risk	of	CVD	for	older	
persons.	However,	treatment	implications	are	patient	to	continued	









ing	 status,	 and	 T2DM	 showed	 predictive	 ability	 in	 people	 aged	
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